Biotest Aktiengesellschaft (BIESF)
USD 32.0
(0.0%)
USD 32.0
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 684.6 Million EUR | 32.65% |
| 2022 | 516.1 Million EUR | 0.1% |
| 2021 | 515.6 Million EUR | 6.48% |
| 2020 | 484.2 Million EUR | 15.53% |
| 2019 | 419.1 Million EUR | 4.7% |
| 2018 | 400.3 Million EUR | 5.87% |
| 2017 | 378.1 Million EUR | -31.64% |
| 2016 | 553.1 Million EUR | -6.19% |
| 2015 | 589.6 Million EUR | 1.31% |
| 2014 | 582 Million EUR | 16.21% |
| 2013 | 500.8 Million EUR | 13.83% |
| 2012 | 439.96 Million EUR | 4.25% |
| 2011 | 422.02 Million EUR | 2.31% |
| 2010 | 412.48 Million EUR | -6.29% |
| 2009 | 440.19 Million EUR | 4.07% |
| 2008 | 422.95 Million EUR | 29.57% |
| 2007 | 326.41 Million EUR | 0.0% |
| 2006 | - EUR | 0.0% |
| 2005 | - EUR | -100.0% |
| 2004 | 217.85 Million EUR | -1.82% |
| 2003 | 221.88 Million EUR | -13.95% |
| 2002 | 257.85 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 156.8 Million EUR | -27.14% |
| 2024 Q1 | 215.2 Million EUR | 16.77% |
| 2023 Q3 | 252.8 Million EUR | 60.0% |
| 2023 Q4 | 184.3 Million EUR | -27.1% |
| 2023 Q2 | 158 Million EUR | 34.81% |
| 2023 Q1 | 117.2 Million EUR | -24.53% |
| 2023 FY | 684.6 Million EUR | 32.65% |
| 2022 Q3 | 107.7 Million EUR | -21.5% |
| 2022 Q4 | 155.3 Million EUR | 44.2% |
| 2022 FY | 516.1 Million EUR | 0.1% |
| 2022 Q1 | 115.9 Million EUR | -19.63% |
| 2022 Q2 | 137.2 Million EUR | 18.38% |
| 2021 Q4 | 144.2 Million EUR | 26.94% |
| 2021 Q1 | 120 Million EUR | -15.85% |
| 2021 Q2 | 137.8 Million EUR | 14.83% |
| 2021 Q3 | 113.6 Million EUR | -17.56% |
| 2021 FY | 515.6 Million EUR | 6.48% |
| 2020 FY | 484.2 Million EUR | 15.53% |
| 2020 Q1 | 97.7 Million EUR | -21.34% |
| 2020 Q2 | 137.1 Million EUR | 40.33% |
| 2020 Q3 | 106.8 Million EUR | -22.1% |
| 2020 Q4 | 142.6 Million EUR | 33.52% |
| 2019 FY | 419.1 Million EUR | 4.7% |
| 2019 Q4 | 124.2 Million EUR | 24.45% |
| 2019 Q3 | 99.8 Million EUR | -15.14% |
| 2019 Q2 | 117.6 Million EUR | 51.74% |
| 2019 Q1 | 77.5 Million EUR | -29.99% |
| 2018 FY | 400.3 Million EUR | 5.87% |
| 2018 Q4 | 110.7 Million EUR | 24.52% |
| 2018 Q3 | 88.9 Million EUR | -21.19% |
| 2018 Q2 | 112.8 Million EUR | 28.18% |
| 2018 Q1 | 88 Million EUR | 29233.33% |
| 2017 FY | 378.1 Million EUR | -31.64% |
| 2017 Q4 | 300 Thousand EUR | -99.77% |
| 2017 Q3 | 130.7 Million EUR | -4.32% |
| 2017 Q2 | 136.6 Million EUR | 23.62% |
| 2017 Q1 | 110.5 Million EUR | 13.33% |
| 2016 Q2 | 159 Million EUR | 8.09% |
| 2016 Q4 | 97.5 Million EUR | -34.78% |
| 2016 Q3 | 149.5 Million EUR | -5.97% |
| 2016 FY | 553.1 Million EUR | -6.19% |
| 2016 Q1 | 147.1 Million EUR | -14.33% |
| 2015 Q3 | 130.2 Million EUR | -10.33% |
| 2015 Q2 | 145.2 Million EUR | 1.89% |
| 2015 Q1 | 142.5 Million EUR | -17.2% |
| 2015 FY | 589.6 Million EUR | 1.31% |
| 2015 Q4 | 171.7 Million EUR | 31.87% |
| 2014 FY | 582 Million EUR | 16.21% |
| 2014 Q3 | 145.8 Million EUR | 2.75% |
| 2014 Q4 | 172.1 Million EUR | 18.04% |
| 2014 Q2 | 141.9 Million EUR | 16.12% |
| 2014 Q1 | 122.2 Million EUR | -8.33% |
| 2013 Q4 | 133.3 Million EUR | 7.33% |
| 2013 FY | 500.8 Million EUR | 13.83% |
| 2013 Q2 | 124.6 Million EUR | 4.97% |
| 2013 Q1 | 118.7 Million EUR | 3.16% |
| 2013 Q3 | 124.2 Million EUR | -0.32% |
| 2012 FY | 439.96 Million EUR | 4.25% |
| 2012 Q2 | 112.5 Million EUR | 4.46% |
| 2012 Q3 | 104.7 Million EUR | -6.93% |
| 2012 Q4 | 115.06 Million EUR | 9.9% |
| 2012 Q1 | 107.7 Million EUR | -2.2% |
| 2011 Q2 | 106.4 Million EUR | -0.09% |
| 2011 Q4 | 110.12 Million EUR | 11.24% |
| 2011 Q3 | 99 Million EUR | -6.95% |
| 2011 FY | 422.02 Million EUR | 2.31% |
| 2011 Q1 | 106.5 Million EUR | 51.75% |
| 2010 Q1 | 115 Million EUR | 4.94% |
| 2010 Q4 | 70.18 Million EUR | -39.08% |
| 2010 Q2 | 112.1 Million EUR | -2.52% |
| 2010 FY | 412.48 Million EUR | -6.29% |
| 2010 Q3 | 115.2 Million EUR | 2.77% |
| 2009 FY | 440.19 Million EUR | 4.07% |
| 2009 Q4 | 109.59 Million EUR | -2.33% |
| 2009 Q3 | 112.2 Million EUR | 2.84% |
| 2009 Q2 | 109.1 Million EUR | -0.18% |
| 2009 Q1 | 109.3 Million EUR | 0.0% |
| 2008 FY | 422.95 Million EUR | 29.57% |
| 2007 FY | 326.41 Million EUR | 0.0% |
| 2006 FY | - EUR | 0.0% |
| 2005 FY | - EUR | -100.0% |
| 2004 FY | 217.85 Million EUR | -1.82% |
| 2003 FY | 221.88 Million EUR | -13.95% |
| 2002 FY | 257.85 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Bioxytran, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -4240.328% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | -3087.448% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -1041465.239% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -3657.822% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | -456.794% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Marizyme, Inc. | 645.81 Thousand USD | -105906.411% |
| Genus plc | 668.8 Million USD | -2.362% |
| Pharming Group N.V. | 245.31 Million USD | -179.069% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -691457.064% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -166808.439% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -891759.147% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -1732275.12% |
| ONE Bio Corp. | 52.29 Million USD | -1209.082% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -1276.883% |
| Mesoblast Limited | 5.9 Million USD | -11499.458% |
| MultiCell Technologies, Inc. | 49.32 USD | -1388077758.881% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -2213.072% |
| Genscript Biotech Corporation | 839.52 Million USD | 18.454% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -3885037.052% |
| Biomind Labs Inc. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -122651.968% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -977900.0% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -903972.685% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -103863.554% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -1399900.0% |
| Q BioMed Inc. | 284.35 Thousand USD | -240657.934% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 95.34% |
| Agentix Corp. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | -371.814% |
| Enzolytics Inc. | 52.79 Thousand USD | -1296589.143% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -112401.541% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 44.174% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -35334.783% |
| HST Global, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -68528428.529% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -488056.187% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -110787.227% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -68516.033% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -1315.808% |
| Kadimastem Ltd | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 16.68 Million USD | -4002.987% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -289298.039% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -289298.039% |
| Affymax, Inc. | 1.36 Million USD | -49907.305% |
| Mobile Lads Corp. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -8689.318% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -144412.697% |
| SYBLEU INC | 11.69 Thousand USD | -5853183.174% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -5266053.846% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -1731574.002% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -20458.559% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -10171.568% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -65790.279% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -2556.887% |
| CSL Limited | 14.8 Billion USD | 95.374% |
| Cellectis S.A. | 755 Thousand USD | -90575.497% |